In CF management, what is the current consensus on omega-3 supplementation?

• A. It has clear, proven benefit; recommended routinely
• B. Evidence is mixed and more trials are needed
• C. It is contraindicated
• D. It is standard care

Answer: (B)

In cystic fibrosis care, omega-3 supplementation is not considered proven or routinely recommended. The evidence from studies is mixed: some small trials show potential improvements in inflammation markers or nutritional parameters, but larger and more rigorous studies have not consistently demonstrated meaningful benefits in lung function, frequency of pulmonary exacerbations, or overall clinical outcomes. Differences in study design, dosing (EPA/DHA ratios and amounts), duration, and participants’ baseline nutrition make it hard to draw a single, definitive conclusion. Meta-analyses often conclude that while omega-3s are safe and may affect inflammation, they do not provide clear, clinically significant improvements, so they are not standard of care. More well-designed trials are needed to identify any subgroups that might benefit and to establish optimal dosing and duration.